Century Therapeutics (IPSC) Net Margin (2022 - 2025)
Historic Net Margin for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to 70.13%.
- Century Therapeutics' Net Margin rose 33522400.0% to 70.13% in Q1 2025 from the same period last year, while for Sep 2025 it was 23.36%, marking a year-over-year increase of 48144800.0%. This contributed to the annual value of 1920.87% for FY2024, which is 41943900.0% up from last year.
- According to the latest figures from Q1 2025, Century Therapeutics' Net Margin is 70.13%, which was up 33522400.0% from 864.44% recorded in Q4 2024.
- In the past 5 years, Century Therapeutics' Net Margin ranged from a high of 70.13% in Q1 2025 and a low of 33627.27% during Q2 2023
- Over the past 4 years, Century Therapeutics' median Net Margin value was 3545.65% (recorded in 2022), while the average stood at 7504.28%.
- Per our database at Business Quant, Century Therapeutics' Net Margin tumbled by -314075000bps in 2023 and then surged by 295796700bps in 2024.
- Over the past 4 years, Century Therapeutics' Net Margin (Quarter) stood at 6081.0% in 2022, then plummeted by -142bps to 14701.87% in 2023, then skyrocketed by 94bps to 864.44% in 2024, then soared by 108bps to 70.13% in 2025.
- Its Net Margin was 70.13% in Q1 2025, compared to 864.44% in Q4 2024 and 3947.66% in Q3 2024.